Intravitreal aflibercept therapy in eyes with chronic central serous chorioretihopathy: Short term results

Tekin, Kemal; Özdal, Pınar; Gulpamuk, Bayram; Teke, Mehmet Yasin

doi:10.1016/j.oftale.2018.05.007

Cited by 3 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eleven out of 20 studies (n=196; 53.3% of all eyes)3 5 22 23 28 31–36 showed statistically significant improvements in BCVA in the anti-VEGF treatment group. Fourteen out of 20 studies (n=268; 79.0% of all eyes)3–5 16 22 23 28 30–36 showed statistically significant reductions in initial CMT after treatment.…”

Section: Resultsmentioning

confidence: 95%

Section: Resultsmentioning

confidence: 99%

“…A total of 20 studies were included in this systematic review (n=339 eyes) 3–5 16 20 22–36. Twelve were prospective studies (n=165),3–5 22–25 29–32 34 seven were retrospective studies (n=173)16 26–28 33 35 36 and one was a case report (n=1) 20. Of the 20 studies, 11 were non-comparative (n=129),3 20 25–32 34 6 studies compared anti-VEGF therapy with other treatment modalities (4 PDT, 1 diode laser, 1 with other anti-VEGF agents) (n=105),4 5 16 23 24 35 3 studies compared observation with anti-VEGF therapy (n=78),22 35 36 and 1 study compared chronic cases of CSR with acute, atypical, or recurrent presentations of the disease (n=46) 33…”

Section: Resultsmentioning

confidence: 99%

“…Two studies used IVA as their treatment modality 30 34. Pitcher et al included 12 patients and compared two injection frequency regimens: 6 patients received IVA 2.0 mg/0.05 mL monthly for 6 months, whereas the remaining 6 patients received intravitreal injections at 0, 1, 2 and 4 months 30.…”

Section: Resultsmentioning

confidence: 99%

“…The number of injections and protocol for re-injection varied across the selected studies. There was an initial injection followed by re-injection at intervals ranging from 4 weeks to 10 months 4 5 16 23–26 28–31 33 34 39. Some protocols had criteria regarding when to re-inject, while others had standard protocol with only one injection used 3 20 22 27 32 35…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature

Palakkamanil¹,

Munro²,

Sethi³

et al. 2023

BMJ Open Ophth

View full text Add to dashboard Cite

ObjectiveThe purpose of this study was to evaluate the role of anti-vascular endothelial growth factor (anti-VEGF) treatment on the functional and structural parameters of chronic central serous retinopathy (CSR).MethodsPubMed was used to systematically review literature published from 1 January 2009 to 1 July 2022. Studies were included if patients in their cohort had symptoms for more than 3 months, anti-VEGF treatment was provided and the following outcomes were reported: best-corrected visual acuity (BCVA), central macular thickness (CMT) and proportion of subretinal fluid (SRF) resolution.Results339 eyes met inclusion criteria with a mean patient age of 45.8±4.9 years. The weighted mean baseline BCVA for the 20 studies was 0.39±0.23 logMAR, which improved to 0.28±0.24 after treatment with anti-VEGF injections (p=0.069). The weighted baseline CMT for the 20 studies decreased from 395.2±52.0 µm to 243.0±41.9 µm (p<0.001). The weighted overall percentage of SRF resolution was 68.4%.ConclusionAnti-VEGF treatment demonstrated significantly decreased macular thickness and resolution of SRF in the treatment of chronic CSR without any reported adverse effects. However, BCVA did not significantly improve with pharmacotherapy.

show abstract

Section: Resultsmentioning

confidence: 95%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature

Palakkamanil¹,

Munro²,

Sethi³

et al. 2023

BMJ Open Ophth

View full text Add to dashboard Cite

show abstract

Effectivness of Intravitreal Ranibizumab (Lucentis) in Acute Central Serous Chorioretinopathy Treatment

Abdulhadi,

Bukhatwa

2024

Ain Shams Medical Journal

View full text Add to dashboard Cite

Background/Aims: To study the effectiveness of intravitreal ranibizumab injection (IVR) in the treatment of acute central serous chorioretinopathy (CSCR).Methods: A Prospective, randomized, single-center, parallel-arm, controlled trial study the involved patients had symptoms of CSCR with less than 3 months duration. Patients (n = 50/ divided into 2 groups) the anti-VEGF group with 30 patients injected with intravitreal Ranibizumab(IVR) (0.5 mg/0.05 ml) and an observation group where 20 patients were observed, each group were followed for 4 months. Best-corrected visual acuity (BCVA), and central macular thickness (CMT) were assessed by Ocular coherent tomography (OCT) for first baseline and then at regular follow-ups.Results: All patients had improved and increased BCVA, with decreased CMT, and resolution of the subretinal fluid. The mean CMT in IVR and observation groups was 117. 33±46.2µm and 196.70±36.9µm, respectively (P = 0.670) The mean BCVA and mean CMT improved significantly in both groups at 4 weeks , but the changes were not significantly different between both groups at 4months. Conclusions: both IVR and observation for acute CSCR improved the resolution of subretinal fluid. BCVA and CMT did not differ at 4 months, between IVR and observation groups. So we advised a Further studies are required to determine the long-term benefits of IVR.

show abstract

Comparison of Intravitreal Bevacizumab and Aflibercept Injections for Central Serous Chorioretinopathy

Park¹,

Lee²

2021

J Korean Ophthalmol Soc

View full text Add to dashboard Cite

Purpose: We examined differences in the treatment effects of intravitreal bevacizumab injections and intravitreal aflibercept injections in patients with central serous chorioretinopathy. Methods: This retrospective analysis included 51 eyes of 49 patients who received intravitreal anti-vascular endothelial growth factor agent injections after initial diagnosis with central serous chorioretinopathy. The patients were divided into two groups: one received an intravitreal bevacizumab injection, and another one received an intravitreal aflibercept injection. Patients with no reaction to treatment or a worsened condition, received repeat treatment with the same therapy. After treatment, patients were monitored for >3 months. Data were collected regarding best- corrected visual acuity (BCVA), subfoveal choroidal thickness, injection number, and treatment duration. Results: Both intravitreal bevacizumab injections and intravitreal aflibercept injections led to significant differences in BCVA (p < 0.0001, p = 0.001) and subfoveal choroidal thickness (p < 0.0001, p = 0.011), compared between before and after treatment. However, no differences between groups were observed in mean change of BCVA or subfoveal choroidal thickness. In addition, there were no differences between groups in injection number and treatment duration. Conclusions: In patients with central serous chorioretinopathy, both intravitreal bevacizumab injections and intravitreal aflibercept injections are effective treatment methods. There were no differences between the two medicines in terms of functional and anatomical recovery, or the injection number and treatment duration.

show abstract

Intravitreal aflibercept therapy in eyes with chronic central serous chorioretihopathy: Short term results

Cited by 3 publications

References 31 publications

Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature

Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature

Effectivness of Intravitreal Ranibizumab (Lucentis) in Acute Central Serous Chorioretinopathy Treatment

Comparison of Intravitreal Bevacizumab and Aflibercept Injections for Central Serous Chorioretinopathy

Contact Info

Product

Resources

About